[Therapeutic options in hormone refractory prostate carcinoma].
Graefen
M
M
Klinik und Poliklinik für Urologie, Universitätsklinik Hamburg-Eppendorf.
Hammerer
P
P
Haese
A
A
Huland
H
H
D000726:Androgen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal
Therapieoptionen des hormonrefraktären Prostatakarzinoms.